Attenuated respiratory syncytial virus vaccine compositions

US5922326A · kind A · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Brian R. Murphy · Bethesda, US
• Robert M. Chanock · Bethesda, US
• James E. Crowe, Jr. · Nashville, US
• Mark Connors · Bethesda, US

Key dates

• Filing date: Oct 21, 1994
• Grant date: Jul 13, 1999
• Expiry date: Oct 21, 2014

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.